Novavax (NVAX) News Today $7.86 -0.06 (-0.76%) As of 10:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025February 20 at 8:00 AM | prnewswire.comNovavax (NVAX) to Release Quarterly Earnings on WednesdayNovavax (NASDAQ:NVAX) will be releasing earnings before the market opens on Wednesday, February 26.February 19 at 3:54 AM | marketbeat.comVontobel Holding Ltd. Sells 67,795 Shares of Novavax, Inc. (NASDAQ:NVAX)Vontobel Holding Ltd. trimmed its stake in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 13.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 430,737 shares of the biopharmaceutical company's stock after selling 67,795 shares during tFebruary 17, 2025 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Receives $17.83 Consensus PT from BrokeragesNovavax, Inc. (NASDAQ:NVAX - Get Free Report) has been assigned a consensus rating of "Hold" from the six ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation anFebruary 15, 2025 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of "Hold" from BrokeragesNovavax, Inc. (NASDAQ:NVAX - Get Free Report) has been given a consensus recommendation of "Hold" by the six brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendatioFebruary 12, 2025 | marketbeat.comBank of America Securities Sticks to Its Hold Rating for Novavax (NVAX)February 12, 2025 | markets.businessinsider.comNovavax, Inc. (NASDAQ:NVAX) About To Shift From Loss To ProfitFebruary 4, 2025 | finance.yahoo.comVaccine, packaged food stocks fall as Kennedy moves closer to health secretary jobFebruary 4, 2025 | reuters.comVaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretaryFebruary 4, 2025 | cnbc.comNovavax, Inc. (NVAX.VI)February 1, 2025 | finance.yahoo.comNovavax (NASDAQ:NVAX) Stock Price Down 5.7% - Should You Sell?Novavax (NASDAQ:NVAX) Trading Down 5.7% - What's Next?January 31, 2025 | marketbeat.comFY2025 EPS Estimates for Novavax Increased by Zacks ResearchNovavax, Inc. (NASDAQ:NVAX - Free Report) - Zacks Research increased their FY2025 EPS estimates for Novavax in a research note issued on Tuesday, January 28th. Zacks Research analyst S. Ganoria now forecasts that the biopharmaceutical company will post earnings per share of ($0.72) for the year,January 31, 2025 | marketbeat.comZacks Research Has Positive Estimate for Novavax Q2 EarningsNovavax, Inc. (NASDAQ:NVAX - Free Report) - Equities research analysts at Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for shares of Novavax in a research note issued to investors on Tuesday, January 28th. Zacks Research analyst S. Ganoria now anticipates that the biophJanuary 30, 2025 | marketbeat.comNovavax (NASDAQ:NVAX) Shares Down 5.7% - Here's WhyNovavax (NASDAQ:NVAX) Stock Price Down 5.7% - What's Next?January 29, 2025 | marketbeat.comNovavax Inc. stock underperforms Monday when compared to competitors despite daily gainsJanuary 27, 2025 | marketwatch.comNovavax, Inc. (NASDAQ:NVAX) is Shah Capital Management's 2nd Largest PositionShah Capital Management lifted its stake in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 13.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,148,846 shares of the biopharmaceutical company's stock afteJanuary 27, 2025 | marketbeat.comNovavax (NASDAQ:NVAX) Stock Price Up 6.1% - Time to Buy?Novavax (NASDAQ:NVAX) Trading Up 6.1% - Should You Buy?January 25, 2025 | marketbeat.comNovavax (NASDAQ:NVAX) Shares Up 6.1% - Here's WhyNovavax (NASDAQ:NVAX) Trading 6.1% Higher - Here's WhyJanuary 23, 2025 | marketbeat.comAnalysts Set Novavax, Inc. (NASDAQ:NVAX) Target Price at $17.83Novavax, Inc. (NASDAQ:NVAX - Get Free Report) has earned a consensus recommendation of "Hold" from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation andJanuary 21, 2025 | marketbeat.comNovavax, Inc. (NVAX) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025January 20, 2025 | insidermonkey.comNovavax, Inc. (NASDAQ:NVAX) Given Consensus Recommendation of "Hold" by BrokeragesShares of Novavax, Inc. (NASDAQ:NVAX - Get Free Report) have been assigned a consensus rating of "Hold" from the six brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three havJanuary 18, 2025 | marketbeat.comNovavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)January 16, 2025 | seekingalpha.comWhy Novavax (NVAX) Stock Is FallingJanuary 13, 2025 | benzinga.comWhy Novavax Stock Is Volatile This WeekJanuary 9, 2025 | benzinga.comBig Movers: Moderna Rose, Palantir, and Applovin FellJanuary 8, 2025 | baystreet.caNovavax (NASDAQ:NVAX) surges 35% this week, taking five-year gains to 171%January 8, 2025 | finance.yahoo.comNovavax (NASDAQ:NVAX) Stock Price Down 8.2% - Time to Sell?Novavax (NASDAQ:NVAX) Stock Price Down 8.2% - Should You Sell?January 8, 2025 | marketbeat.comVaccine Stocks Jump on U.S. Bird-Flu DeathJanuary 7, 2025 | wsj.comOptions Alert: Why Novavax (NVAX) Could Be the Biotech Hero of Trump 2.0January 7, 2025 | msn.comNovavax (NASDAQ:NVAX) Sees Large Volume Increase - Should You Buy?Novavax (NASDAQ:NVAX) Sees Strong Trading Volume - Here's WhyJanuary 7, 2025 | marketbeat.comNovavax Target of Unusually High Options Trading (NASDAQ:NVAX)Novavax, Inc. (NASDAQ:NVAX - Get Free Report) saw unusually large options trading on Tuesday. Stock traders bought 41,513 call options on the company. This represents an increase of 109% compared to the average volume of 19,859 call options.January 7, 2025 | marketbeat.comWhy Novavax (NVAX) Stock Is RisingJanuary 7, 2025 | benzinga.comModerna, Novavax and other vaccine names extend gains amid COVID/flu concernsJanuary 7, 2025 | seekingalpha.comInsider Sell: James Young Sells 10,000 Shares of Novavax Inc (NVAX)January 3, 2025 | gurufocus.comInsider Selling: Novavax, Inc. (NASDAQ:NVAX) Director Sells 4,150 Shares of StockJanuary 3, 2025 | insidertrades.comRachel K. King Sells 4,150 Shares of Novavax, Inc. (NASDAQ:NVAX) StockNovavax, Inc. (NASDAQ:NVAX - Get Free Report) Director Rachel K. King sold 4,150 shares of the business's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the transaction, the director now directly owns 14,770 shares in the company, valued at $133,225.40. This represents a 21.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.January 2, 2025 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Director James F. Young Sells 4,600 SharesNovavax, Inc. (NASDAQ:NVAX - Get Free Report) Director James F. Young sold 4,600 shares of the stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total transaction of $39,008.00. Following the completion of the sale, the director now directly owns 57,160 shares of the company's stock, valued at approximately $484,716.80. This trade represents a 7.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.January 2, 2025 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Director James F. Young Sells 5,400 SharesNovavax, Inc. (NASDAQ:NVAX - Get Free Report) Director James F. Young sold 5,400 shares of the company's stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total value of $43,200.00. Following the completion of the sale, the director now directly owns 51,760 shares in the company, valued at approximately $414,080. The trade was a 9.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.January 2, 2025 | marketbeat.comNovavax director James Young sells shares worth $82,208January 2, 2025 | investing.comNovavax director Rachel King sells $37,435 in stockJanuary 2, 2025 | investing.comNovavax (NASDAQ:NVAX) Stock Price Up 6.6% - Should You Buy?Novavax (NASDAQ:NVAX) Stock Price Up 6.6% - Time to Buy?January 2, 2025 | marketbeat.comNovavax (NASDAQ:NVAX) Stock Price Down 5.8% - Time to Sell?Novavax (NASDAQ:NVAX) Stock Price Down 5.8% - What's Next?December 30, 2024 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Stock Holdings Boosted by Franklin Resources Inc.Franklin Resources Inc. lifted its position in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 300.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 97,162 shares of the biopharmaceutical company's stock after buying an additional 72,8December 28, 2024 | marketbeat.comGeode Capital Management LLC Has $44.25 Million Stake in Novavax, Inc. (NASDAQ:NVAX)Geode Capital Management LLC raised its position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 9.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,502,489 shares of the biopharmaceutical compDecember 24, 2024 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by AnalystsShares of Novavax, Inc. (NASDAQ:NVAX - Get Free Report) have received a consensus recommendation of "Hold" from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and thrDecember 24, 2024 | marketbeat.comWellington Management Group LLP Acquires New Holdings in Novavax, Inc. (NASDAQ:NVAX)Wellington Management Group LLP bought a new position in Novavax, Inc. (NASDAQ:NVAX - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The fund bought 73,115 shares of the biopharmaceutical company's stock, valued at approximately $923,000. A nDecember 20, 2024 | marketbeat.comNovavax (NASDAQ:NVAX) Stock Quotes, Forecast and News SummaryDecember 19, 2024 | benzinga.comNovavax says Australia cancels delivery of some Covid-19 dosesDecember 18, 2024 | tipranks.comNovavax, Inc. (NASDAQ:NVAX) Shares Acquired by Barclays PLCBarclays PLC boosted its stake in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 73.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 709,579 shares of the biopharmaceutical company's stock afteDecember 18, 2024 | marketbeat.comState Street Corp Purchases 1,621,772 Shares of Novavax, Inc. (NASDAQ:NVAX)State Street Corp lifted its holdings in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 26.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,687,951 shares of the biopharmaceutical company's stock afteDecember 17, 2024 | marketbeat.com Get Novavax News Delivered to You Automatically Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address NVAX Media Mentions By Week NVAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVAX News Sentiment▼0.540.60▲Average Medical News Sentiment NVAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVAX Articles This Week▼410▲NVAX Articles Average Week Get Novavax News Delivered to You Automatically Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ionis Pharmaceuticals News Amicus Therapeutics News Ligand Pharmaceuticals News BioCryst Pharmaceuticals News Dynavax Technologies News Geron News Celldex Therapeutics News MannKind News Myriad Genetics News Innoviva News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NVAX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
